drugset / Trial / NCT03929172

A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects

NCT03929172 ↗

Phase 1 Completed 20 enrolled 2A Pharma AB Celerion · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the safety, tolerability, and the immunological effects of adeno-associated virus-like particle human papillomavirus (AAVLP-HPV) vaccine in healthy adults.

Timeline

Start
2019-02-28
Primary completion
2020-05-29
Completion
2020-05-29

Drugs

EvaluationDrugModalityDoseRoute
Subject AAVLP-HPV Vaccine 20 ug Intramuscular